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Particulate matter (PM) air pollution, espe-
cially from combustion sources, is associated 
with adverse cardiovascular outcomes (Brook 
2008; Mills et al. 2009). Identifying source-
specific PM health effects is of practical con-
cern for prevention efforts, and traffic-related 
particles (TRPs) have been of special interest. 
Short-term transient exposure to TRPs has 
been associated with increased daily mortality 
(Laden et al. 2000), acute myocardial infarc-
tion (Lanki et al. 2006; Peters et al. 2004; 
Zanobetti and Schwartz 2006), and high 
blood pressure (Delfino et al. 2010). Several of 
these studies suggest greater toxicity associated 
with TRP exposure than with other sources 
of PM (Laden et al. 2000; Peters et al. 2004; 
Zanobetti and Schwartz 2006). Furthermore, 
studies of intermediate cardiovascular health 
effects also suggest greater toxicity associated 
with TRPs, as indicated by stronger inflam-
matory, coagulatory, and cardiac autonomic 
nervous system responses (Park et al. 2008; 
Schwartz et al. 2005; Zeka et al. 2006).
Although the exact biological mechanisms 
by which TRPs exert effects on the cardio-
vascular system are still unclear, there is strong 
evidence that inflammation is involved in the 
pathophysiological responses to PM inhalation 
(Brook et al. 2003; Donaldson et al. 2001; 
Pope and Dockery 2006). In studies of TRP 
exposures, associations with inflammatory 
markers have been observed in the elderly 
(Zeka et al. 2006), individuals with diabetes 
(O’Neill et al. 2007), young healthy male 
highway patrol troopers (Riediker et al. 2004), 
and elderly individuals with coronary artery 
disease (Delfino et al. 2009). Furthermore, 
studies suggest that individuals with diabetes 
and coronary heart disease (CHD), diseases 
associated with systemic inflammation, are 
likely to be more susceptible to systemic 
inflammation in response to PM exposure 
(Delfino et al. 2008; Dubowsky et al. 2006; 
Rioux et al. 2010).
TRPs are generally a mixture of tailpipe 
emissions of combustion PM, tire- and break-
wear PM, and mineral PM from road pave-
ment abrasion. Black carbon (BC), a specific 
component of PM2.5 (PM with aerodynamic 
diameter ≤ 2.5 μm) resulting from incom-
plete combustion, is a widely used surrogate 
of TRPs (Janssen et al. 2011). Although other 
sources may contribute to BC, few sources 
other than traffic contribute to BC in the 
Boston area where this study was conducted 
(Gryparis et al. 2007).
The present study was designed to inves-
tigate the relationship between short-term 
exposure to modeled residential concentra-
tions of BC and markers of systemic inflam-
mation in a group of elderly males with 
and without chronic health conditions and 
to determine whether CHD, diabetes, and 
obesity modify associations between BC 
and markers of inflammation. Exposure to 
BC was estimated from a validated land-use 
regression model that incorporated tempo-
ral effects and space-time interactions and 
was assigned at the individual level (Gryparis 
et al. 2007). Circulating markers of systemic 
inflammation were the pro  -inflammatory 
cytokines interleukin (IL)-1β, IL-6, IL-8, 
tumor necrosis factor-α (TNF-α), and vascu-
lar endothelial growth factor (VEGF), as well 
as the soluble TNF receptor-2 (sTNF-RII) 
and the acute-phase protein C-reactive pro-
tein (CRP). These markers, associated with 
CHD and other inflammatory-related diseases 
to varying degrees, are commonly assessed 
in air pollution studies and were chosen to 
reflect both early and later acute phase sys-
temic inflammatory responses, providing a 
more comprehensive understanding of the 
exposure-elicited biological mechanisms. We 
investigated changes in these markers with 
respect to exposure from 1 day up to 4 weeks.
Address correspondence to S.C.  Fang,  665 
Huntington Ave., Building 1, Room 1411, Boston, 
MA 02115 USA. Telephone: (617) 432-6460. Fax: 
(617) 432-6981. E-mail: sfang@hsph.harvard.edu
Supplemental Material is available online (http://
dx.doi.org/10.1289/ehp.1103982). 
We thank K. Feng, M. Wang, E. Dibbs, T. Kotlov, 
and H. Guan. 
This research was supported by National Institutes 
of Health grant 1R01 ES014663-01A2 and Harvard–
National Institute for Occupational Safety and 
Health Education and Research Center Pilot Project 
grant T42 OH008416-04. The VA Normative 
Aging Study is supported by the Cooperative Studies 
Program/Epidemiology Research and Information 
Center (ERIC) of the Department of Veterans 
Affairs and is a component of the Massachusetts 
Veterans Epidemiology Research and Information 
Center (MAVERIC). S.C. Fang was supported by an 
award from the American Heart Association.
The authors declare they have no actual or potential 
competing financial interests.
Received 24 May 2011; accepted 15 February 
2012.
Residential Black Carbon Exposure and Circulating Markers of Systemic 
Inflammation in Elderly Males: The Normative Aging Study
Shona C. Fang,1 Amar J. Mehta,1,2,3 Stacey E. Alexeeff,1 Alexandros Gryparis,4 Brent Coull,5 Pantel Vokonas,6,7 
David C. Christiani,1,8 and Joel Schwartz1
1Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA; 2Chronic Disease Epidemiology 
Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland; 3Department of Public Health, University of Basel, Basel, 
Switzerland; 4Department of Applied Mathematics, University of Crete, Crete, Greece; 5Department of Biostatistics, Harvard School 
of Public Health, Boston, Massachusetts, USA; 6VA Normative Aging Study, Veterans Affairs Boston Healthcare System, Boston, 
Massachusetts, USA; 7Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA; 8Department of 
Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
Ba c k g r o u n d: Traffic-related particles (TRPs) are associated with adverse cardiovascular events. 
The exact mechanisms are unclear, but systemic inflammatory responses likely play a role. 
oBjectives: We conducted a repeated measures study among male participants of the Normative 
Aging Study in the greater Boston, Massachusetts, area to determine whether individual-level resi-
dential black carbon (BC), a marker of TRPs, is associated with systemic inflammation and whether 
coronary heart disease (CHD), diabetes, and obesity modify associations.
Me t h o d s : We quantified markers of inflammation in 1,163 serum samples from 580 men. 
Exposure to BC up to 4 weeks prior was predicted from a validated spatiotemporal land-use regres-
sion model. Linear mixed effects models estimated the effects of BC on each marker while adjusting 
for potential confounders.
re s u l t s: Associations between BC and blood markers were not observed in main effects models or 
when stratified by obesity status. However, BC was positively associated with markers of inflamma-
tion in men with CHD (particularly vascular endothelial growth factor) and in men with diabetes 
(particularly interleukin-1β and tumor necrosis factor-α). Significant exposure time windows varied 
by marker, although in general the strongest associations were observed with moving averages of 
2–7 days after a lag of several days.
co n c l u s i o n s: In an elderly male population, estimated BC exposures were positively associated 
with markers of systemic inflammation but only in men with CHD or diabetes.
key w o r d s : air pollution, black carbon, cardiovascular disease, coronary heart disease, diabetes, 
inflammation, land-use regression model, particulate matter, susceptible, traffic. Environ Health 
Perspect 120:674–680 (2012).  http://dx.doi.org/10.1289/ehp.1103982 [Online 15 February 2012]Residential black carbon and systemic inflammation
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Materials and Methods
Study population. The study population con-
sisted of a subset of participants from the 
Normative Aging Study, a community-based 
longitudinal study of aging among 2,280 
men from the greater Boston, Massachusetts, 
area (21–81 years of age at study entry) that 
was initiated in 1963 by the U.S Veterans 
Affairs Outpatient Clinic in Boston (Bell 
et al. 1966). Participants were free of known 
medical conditions at enrollment and were 
asked to visit the clinic every 3–5 years for 
a detailed examination, including a routine 
physical examination, laboratory tests, collec-
tion of medical history and social status infor-
mation, and administration of questionnaires 
on medication use, smoking history, alcohol 
consumption, food intake, and other factors 
that may influence health. Participants vis-
ited the study center in the morning after an 
overnight fast and abstinence from smoking. 
Men were classified as having CHD based on 
a physician diagnosis of nonfatal myocardial 
infarction or angina pectoris [International 
Classification of Diseases, 8th revision (World 
Health Organization 1967) codes 410–414] 
and were classified as having diabetes based 
on a physician’s diagnosis of diabetes mel-
litus and/or fasting blood glucose levels > 126 
mg/dL. Obesity was defined as body mass 
index (BMI) ≥ 30 kg/m2. Follow-up has been 
excellent, with loss of < 1% of subjects per 
year, primarily because of death (n = 728) 
or moving out of the region. A total of 580 
Massachusetts residents with archived serum 
samples collected between 2000 and 2008 
were included in the present study. All par-
ticipants provided written informed consent 
before study procedures. The present study 
protocol was approved by the Institutional 
Review Board of the Harvard School of 
Public Health.
Exposure assessment. Individual-level esti-
mates of residential BC concentrations were 
predicted from a validated spatio  temporal 
land-use regression model. Details of this 
model are presented elsewhere (Gryparis et al. 
2007; Suglia et al. 2008). In brief, BC was 
measured using an aethalometer at more than 
80 locations in the greater Boston area, of 
which three-quarters were residential; the rest 
were commercial or government facilities. 
These measurements were used to calibrate 
a model predicting concentrations based on 
BC measurements at a central location (to 
capture regional day effects), land-use terms 
(e.g., traffic density, open space) at each of 
the calibration monitors, weather parameters, 
height of the planetary boundary layer, and 
interactions of these parameters. Penalized 
splines were used to capture nonlinearities in 
dependence, and thin plate splines of latitude 
and longitude were used to capture remain-
ing spatial variability. The exposure model 
predicted 24-hr measures of BC. Daily BC 
measurements, presented as micrograms per 
cubic meter, were lagged up to 1 week and 
averaged up to 4 weeks before the visit date.
Collection and analysis of blood sam-
ples. Study staff collected blood samples by 
venous puncture in the morning after over-
night fast at each study visit. We quantified 
serum marker levels in-house using multiplex-
ing technology (MILLIPLEXTM MAP) with 
commercially available MILLIPLEXTM MAP 
kits (EMD Millipore, Billerica, MA, USA). In 
brief, the technology uses color-coded micro-
spheres (beads) that are each coated with a 
specific capture antibody. A small amount 
of serum sample (25 μL) is added, and the 
analyte is captured onto the bead. Circulating 
cytokines IL-1β, IL-6, TNF-α, IL-8, VEGF, 
and sTNF-RII were assayed from serum 
(MILLIPLEX Human Cytokine/Chemokine; 
EMD Millipore) and quantified using the 
Luminex® 200™ System multiplex detection 
system (Luminex Corporation, Austin, TX, 
USA). We monitored the performance of the 
assays with standard quality control proce-
dures, including analysis of blinded pooled 
samples. Values for which the percent recov-
ery of the standards was < 70% or > 130% 
were excluded from analysis. This led to the 
exclusion of 260 (22%) VEGF values. All 
data were normalized for interbatch variation.
Serum high-sensitivity CRP was mea-
sured at the reference laboratory at Children’s 
Hospital, Boston, using the immuno-
turbidi  metric assay on the Hitachi 917 ana-
lyzer (Roche Diagnostics, Indianapolis, IN, 
USA) with reagents and calibrators from 
DenkaSeiken (Niigata, Japan). To control for 
acute inflammation or infection, any obser-
vations for which CRP was ≥ 10 mg/L were 
excluded from analysis (n = 54) (Pearson 
et al. 2003).
Statistical analysis. Linear mixed effects 
models with random intercepts, which account 
for the correlation of repeated measures, were 
used to estimate the associa  tion between 
exposure to BC and the bio  markers of interest. 
Outcome data were natural log transformed 
to improve the normality of the residuals. For 
each bio  marker, associations with daily BC in 
the 24 hr preceding the blood draw—lagged 
up to 7 days and averaged over periods ranging 
from 1 day to 4 weeks—were investigated in 
separate models. Based on associations with 
individual lags, we also assessed associations 
with lagged moving averages. An unstructured 
covariance matrix was chosen as the working 
covariance structure because it provided the 
lowest Akaike information criterion. A priori–
selected potential confounders (classified 
at each visit) included in the models were 
the continuous variables of age, pack-years 
of cigarettes smoked, fasting blood glucose 
level, BMI, and apparent temperature for 
the 24 hr before the clinic visit (measured at 
Logan Airport) and the categorical variables of 
alcohol consumption (> 2 vs. < 2 drinks/day),   
calendar year, season, and medication use 
(antihypertensives, statins, and/or non  steroidal 
anti-inflammatory drugs). We estimated 
the percent change and 95% confidence 
intervals (CIs) in each blood marker for an 
increase in the exposure equal to the average 
interquartile range (IQR) of the BC exposure 
window concentrations (0.36  μg/m3).   
To assess potential differences between those 
with repeat visits and only one visit, we 
conducted a sensitivity analysis restricting the 
main effects models to those with repeated 
observations only.
To evaluate effect modification by CHD, 
diabetes, and obesity, separate models were 
constructed including interaction terms 
between each condition and the BC exposure 
metric. The general form of the model was 
Yij = β0 + β1BCij + β2CHDij  
  + β3(BC × CHD)ij + βZij + b0i + eij, 
where, for the ith individual at the jth meas-
urement occasion, BC is the continuous mov-
ing average or daily lag, CHD = 1 for presence 
of CHD and 0 otherwise, BC × CHD is the 
cross-product between exposure and CHD 
status, Z is a vector of covariates, and b0i is a 
random intercept for the ith individual.
Residual plots and the distributions of 
error terms were assessed to check the nor-
mality of the residuals and adequacy of model 
fits. Statistical significance for all testing was 
considered at the α = 0.05 level. Analyses 
were performed with SAS (version 9.2; SAS 
Institute Inc., Cary, NC, USA).
Results
A total of 580 males were included in the 
analysis (Table 1). At the first study visit 
starting in 2000, the average age was 73 years 
(range, 57–100 years); 4% were current 
smokers, and 67% were former smokers. 
Blood samples were collected one to four 
times for each participant (median = 2) for 
a total of 1,163 measurements. At first visit, 
175 participants (30%) had CHD, 107 (18%) 
had diabetes, and 153 (26%) were obese. 
Over the course of the study, an additional 
38 developed CHD, 31 developed diabetes, 
and 26 became obese. The median estimated 
24-hr residential BC concentration before the 
baseline clinic visit was 0.39 μg/m3 (range, 
0.01–3.84 μg/m3). Spearman rank correlation 
coefficients (rS) showed weak (rS < 0.30) to 
moderate (rS = 0.30–0.70) correlations among 
the blood markers, with the exception of 
IL-6 and IL-8 (rS = 0.71), VEGF and IL-8 
(rS = 0.77), and VEGF and IL-6 (rS = 0.74; 
Table 2). CRP was weakly correlated with all 
blood markers. Similar correlation patterns Fang et al.
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were observed across subpopulations by 
health condition (data not shown), although 
correlations were slightly stronger between 
some markers among men with diabetes 
(TNF-α and IL-1β, rS = 0.53; TNF-α and 
IL-6, rS = 0.62; VEGF and IL-1β, rS = 0.50) 
and obesity (VEGF and IL-1β, rS = 0.57).
Results from univariate and multivariable 
main effects models were similar, and thus only 
selected results from multivariable models are 
presented (Table 3). In the main effects mod-
els, we did not observe consistent patterns of 
association between the blood markers and 
estimated daily BC averaged over periods of up 
to 4 weeks [see Supplemental Material, Table 1 
(http://dx.doi.org/10.1289/ehp.1103982)] or 
single-day BC lagged up to 7 days (Table 3). In 
general, effect estimates were close to the null 
without consistent direction, and CIs widely 
overlapped zero. In a sensitivity analysis, we 
restricted the main effects models to those with 
repeated observations (n = 425), finding that 
overall patterns and magnitudes of the effect 
estimates were similar (data not shown).
Effect modification by CHD, diabetes 
mellitus, and obesity. In models investigat-
ing modification by CHD status (interaction 
p-value, < 0.01 to 0.99), stratum-specific 
effect estimates were generally null for those 
without CHD, whereas among those with 
CHD over the study period (total n = 213), 
IL-6, VEGF, and TNF-α increased with BC 
at later lags [e.g., IL-6 increased 25.6% at 
lag 4 (95% CI: 7.2, 47.1; interaction p-value 
< 0.01), VEGF increased 10.2% at lag 5 (95% 
CI: –0.2, 21.8; interaction p-value = 0.12), 
and TNF-α increased 13.2% at lag 4 (95% 
CI: 1.9, 25.8; interaction p-value = 0.02)] but 
not with earlier lags (Table 4). No associa-
tions were observed with the unlagged moving 
averages [see Supplemental Material, Table 2 
(http://dx.doi.org/10.1289/ehp.1103982)]. 
Associations with lagged exposures continued 
to be observed when exposures were averaged 
over a period of up to 1 week for IL-6 (lag 4, 
7-day moving average; 24.9%; 95% CI: 2.3, 
52.6; interaction p-value = 0.04) and VEGF 
(lag 5, 6-day moving average; 22.6%; 95% CI: 
8.0, 39.2; interaction p-value = 0.02) but not 
for TNF-α (Figure 1; see also Supplemental 
Material, Table 4). Restricting analyses to 
those with CHD only (i.e., without diabetes, 
total n = 155) resulted in attenuated effect 
estimates (Figure 1).
When stratified by diabetes status (inter-
action p-value, < 0.001 to 0.99), associations 
for those without diabetes were also gener-
ally null, with the exception of significant 
inverse associations with nearly all exposure 
windows for IL-1β (Table 5). Among those 
with diabetes over the study period (total 
n = 138), significant positive associations were 
observed with nearly all exposure windows 
for IL-1β and with later daily lags for IL-6, 
IL-8, and TNF-α [e.g., IL-6 increased 55.1% 
at lag 3 (95% CI: 16.7, 106.3; interaction 
p-value < 0.01), and IL-8 increased 19.9% 
Table 1. Characteristics of male study participants at first study visit (n = 580).
Characteristic Value
Race
White 557 (96.0)
Black 13 (2.2)
Hispanic white 2 (0.3)
Unknown 8 (1.4)
Smoking status
Current 23 (4.0)
Former 391 (67.4)
Never 166 (28.6)
Alcohol consumption (> 2 drinks/day) 102 (17.6)
Physician-diagnosed medical conditions
CHD 175 (30.2)
Diabetes or fasting blood glucose > 126 mg/dL 107 (18.4)
Medication use
Antihypertensive medications 361 (62.2)
Statins 240 (41.4)
Nonsteroidal anti-inflammatory drugs 346 (59.7)
Age (years) [mean (range)] 73 (57–100)
BMI (kg/m2) (mean ± SD) 28.3 ± 4.2
Obese (≥ 30 kg/m2) 153 (26.4)
Not obese (< 30 kg/m2) 427 (73.6)
Pack-years among ever smokers [median (range)] 29.9 (< 1–131)
Inflammatory marker levels [median (25th–75th percentile)]
IL-1 (pg/mL) 2.6 (1.2–13.8)
IL-6 (pg/mL) 31.3 (5.3–169.4)
IL-8 (pg/mL) 45.7 (23.8–94.8)
VEGF (pg/mL; n = 451) 836.0 (267.5–1376.1)
TNF- (pg/mL) 15.2 (7.2–39.9)
sTNF-RII (ng/mL) 5.6 (4.4–7.0)
CRP (mg/L; n = 536) 1.6 (0.8–3.2)
Values are n (%) unless otherwise specified.
Table 2. Spearman rank correlations between inflammatory markers at baseline [rS (p-value)].
Marker IL-6 IL-8 TNF-α VEGF sTNF-RII CRP
IL-1β 0.55 (< 0.0001) 0.53 (< 0.0001) 0.44 (< 0.0001) 0.46 (< 0.0001) 0.07 (0.11) 0.02 (0.69)
IL-6 0.71 (< 0.0001) 0.54 (< 0.0001) 0.74 (< 0.0001) 0.14 (0.001) 0.03 (0.51)
IL-8 0.52 (< 0.0001) 0.77 (< 0.0001) 0.20 (< 0.0001) 0.04 (0.41)
TNF-α 0.48 (< 0.0001) 0.17 (< 0.0001) 0.09 (0.04)
VEGF 0.18 (< 0.0001) –0.02 (0.73)
sTNF-RII 0.19 (< 0.0001)
Table 3. Percent change in blood marker per IQR 
(0.36 μg/m3) increase in BC.
Marker/single-day 
exposure lag Change [% (95% CI)] p-Value
IL-1β
Lag 0 –2.2 (–8.2, 4.2) 0.48
Lag 1 –3.0 (–9.5, 4.0) 0.40
Lag 3 –7.2 (–15.6, 2.1) 0.12
Lag 4 –2.4 (–9.5, 5.3) 0.53
Lag 5 –3.5 (–10.3, 3.8) 0.34
IL-6
Lag 0 –1.0 (–9.1, 7.8) 0.82
Lag 1 –3.8 (–11.7, 4.7) 0.37
Lag 3 6.4 (–4.4, 18.5) 0.25
Lag 4 1.8 (–6.1, 10.4) 0.66
Lag 5 –0.1 (–7.5, 7.9) 0.97
IL-8
Lag 0 1.0 (–3.3, 5.4) 0.66
Lag 1 –1.0 (–4.8, 3.0) 0.62
Lag 3 –2.0 (–7.4, 3.6) 0.47
Lag 4 –0.1 (–4.1, 4.1) 0.97
Lag 5 1.0 (–2.7, 4.9) 0.59
VEGF
Lag 0 3.3 (–2.7, 9.6) 0.29
Lag 1 –0.1 (–6.1, 6.2) 0.96
Lag 3 0.4 (–6.2, 7.5) 0.90
Lag 4 0.8 (–4.5, 6.4) 0.78
Lag 5 2.6 (–2.4, 7.9) 0.32
TNF-α
Lag 0 –0.9 (–5.4, 3.8) 0.70
Lag 1 –1.2 (–5.8, 3.7) 0.63
Lag 3 –0.4 (–7.0, 6.7) 0.91
Lag 4 1.9 (–3.0, 7.0) 0.46
Lag 5 0.9 (–3.5, 5.6) 0.68
sTNF-RII
Lag 0 0.2 (–1.8, 2.3) 0.82
Lag 1 –0.3 (–2.5, 1.9) 0.76
Lag 3 –0.1 (–2.7, 2.7) 0.97
Lag 4 0.8 (–1.4, 3.0) 0.50
Lag 5 0.9 (–1.2, 3.0) 0.39
CRP
Lag 0 –0.4 (–5.3, 4.7) 0.87
Lag 1 4.8 (–0.7, 10.6) 0.09
Lag 3 –1.2 (–7.8, 6.0) 0.74
Lag 4 –2.7 (–8.1, 3.1) 0.35
Lag 5 –3.1 (–7.5, 1.5) 0.18
Models were adjusted for age, BMI, calendar year, pack-
years, medication use, season, fasting glucose level, 
alcohol consumption, and apparent temperature.Residential black carbon and systemic inflammation
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at lag 4 (95% CI: 5.3, 36.4; interaction 
p-value < 0.01), and TNF-α increased 17.7% 
at lag 3 (95% CI: 0.3, 38.1; interaction 
p-value = 0.14)]. IL-6 was also associated with 
unlagged moving average exposures starting 
at 5 days [see Supplemental Material, Table 3 
(http://dx.doi.org/10.1289/ehp.1103982)]. 
We also observed a consistent pattern of posi-
tive associations with these markers for longer 
exposure windows for lag 3 (IL-6, TNF-α) 
and lag 4 (IL-8; Figure 2). After excluding 
those with CHD (n = 71), a smaller range of 
exposure windows were significantly associ-
ated with IL-1β, although point estimates 
were similar. For IL-6, estimated effects were 
attenuated (Figure 2; see also Supplemental 
Material, Table 5). Effect estimates remained 
similar for IL-8 and TNF-α.
We also estimated associations among 
those with both CHD and diabetes (n = 76), 
finding that for IL-6 and IL-8, associations 
with BC were stronger than those for either 
condition alone (Figure 2). We did not assess 
the effect of obesity in addition to CHD and 
diabetes because few observations (< 3%) 
were characterized by the presence of all three 
conditions.
Discussion
Using individual-level exposure estimates of 
BC in a relatively large panel of elderly males 
with repeated measurements, the results of 
this study suggest that estimated BC expo-
sures are associated with increases in markers 
of systemic inflammation, but only in indi-
viduals with CHD, diabetes, or both CHD 
and diabetes. Our findings also suggest that 
the effects of exposure may occur after a lag 
period of days and may be observed with daily 
exposures averaged up to 7 days. We did not 
observe associations in the cohort as a whole.
Among individuals with CHD, BC was 
associated with IL-6, VEGF, and TNF-α. 
However, VEGF, a growth factor related to 
angiogenesis, was most consistently associated 
with BC after restricting analyses to those with 
CHD only (i.e., without diabetes) and using 
different lagged averaging periods. Exclusion 
of individuals with diabetes resulted in atten-
uated effect estimates for IL-6, VEGF, and 
TNF-α, suggesting that some of the effects 
were attributable to individuals with diabetes. 
Specifically, 27% of those with CHD also 
had diabetes. IL-6 and VEGF are elevated in 
CHD and have been shown to predict CHD 
events (Cesari et al. 2003; Danesh et al. 2008; 
Eaton et al. 2008). Among men with CHD, 
these markers were increased in association 
with exposure after a 4- or 5-day lag, (i.e., 
exposure occurred 5 and 6 days before the 
date of visit), suggesting a delay in the pro-
duction or release of these markers into the 
circulatory system. Alternatively, there may 
be a slow rise in the concentrations of these 
Figure 1. Percent change in blood marker per IQR increase in lagged mean residential BC by CHD status.
aInteraction p-values, < 0.01 to 0.29.bInteraction p-values, 0.13–0.50. BC exposure window, days of moving average.
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Table 4. Percent change in blood marker per IQR (0.36 μg/m3) increase in daily BC by CHD status.
Marker/single-day   
exposure lag
Without CHD With CHD Interaction 
p-value Change [% (95% CI)] p-Value Change [% (95% CI)] p-Value
IL-1β
Lag 0 –4.1 (–11.8, 4.3) 0.33 1.5 (–6.6, 10.3) 0.73 0.34
Lag 1 –7.0 (–15.1, 1.9) 0.12 3.1 (–7.3, 14.7) 0.58 0.14
Lag 3 –8.2 (–18.1, 3.0) 0.14 –4.9 (–17.8, 10.0) 0.50 0.70
Lag 4 –4.0 (–11.5, 4.2) 0.33 3.9 (–11.7, 22.3) 0.64 0.39
Lag 5 –5.3 (–12.1, 1.9) 0.15 3.6 (–10.9, 20.4) 0.65 0.28
IL-6
Lag 0 1.1 (–8.2, 11.4) 0.83 –4.9 (–18.1, 10.3) 0.50 0.48
Lag 1 –5.9 (–16.3, 5.8) 0.31 –1.0 (–11.9, 11.3) 0.87 0.54
Lag 3 2.1 (–9.9, 15.7) 0.74 16.3 (–2.3, 38.5) 0.09 0.22
Lag 4 –4.2 (–12.5, 4.9) 0.36 25.6 (7.2, 47.1) < 0.01 < 0.01
Lag 5 –3.4 (–11.3, 5.3) 0.43 12.7 (–4.0, 32.4) 0.14 0.09
IL-8
Lag 0 2.7 (–2.0, 7.7) 0.27 –2.3 (–9.1, 4.9) 0.52 0.23
Lag 1 –1.7 (–6.4, 3.2) 0.49 0.1 (–5.8, 6.3) 0.98 0.64
Lag 3 –2.0 (–7.6, 4.1) 0.51 –2.3 (–12.9, 9.6) 0.69 0.96
Lag 4 –1.4 (–5.4, 2.9) 0.53 4.0 (–6.2, 15.3) 0.45 0.34
Lag 5 –0.3 (–4.3, 3.8) 0.88 6.1 (–2.2, 15.0) 0.15 0.16
VEGF
Lag 0 4.1 (–2.9, 11.6) 0.26 1.6 (–8.4, 12.7) 0.76 0.70
Lag 1 0.4 (–7.1, 8.6) 0.91 –1.0 (–9.9, 8.8) 0.83 0.81
Lag 3 1.2 (–6.5, 9.6) 0.76 –0.8 (–12.9, 12.9) 0.90 0.79
Lag 4 –0.5 (–6.2, 5.5) 0.86 5.2 (–7.1, 19.1) 0.42 0.42
Lag 5 0.8 (–4.7, 6.7) 0.77 10.2 (–0.2, 21.8) 0.05 0.12
TNF-α
Lag 0 0.7 (–5.0, 6.7) 0.82 –4.0 (–10.6, 3.2) 0.27 0.31
Lag 1 –1.5 (–7.5, 4.8) 0.63 –0.7 (–7.9, 7.1) 0.86 0.87
Lag 3 –0.7 (–8.7, 8.1) 0.87 0.2 (–10.2, 11.8) 0.97 0.90
Lag 4 –1.3 (–6.2, 3.8) 0.60 13.2 (1.9, 25.8) 0.02 0.02
Lag 5 –1.6 (–5.9, 3.0) 0.50 10.9 (1.0, 21.7) 0.03 0.02
sTNF-RII
Lag 0 1.2 (–1.2, 3.6) 0.32 –1.5 (–4.8, 1.9) 0.38 0.20
Lag 1 0.5 (–2.1, 3.1) 0.72 –1.4 (–4.9, 2.2) 0.45 0.40
Lag 3 0.5 (–2.7, 3.7) 0.77 –1.2 (–5.5, 3.3) 0.60 0.54
Lag 4 1.3 (–1.2, 3.9) 0.32 –0.8 (–4.8, 3.4) 0.72 0.40
Lag 5 1.7 (–0.6, 4.0) 0.15 –1.5 (–4.9, 2.1) 0.42 0.14
CRP
Lag 0 –1.5 (–7.3, 4.6) 0.62 1.5 (–6.7, 10.4) 0.73 0.56
Lag 1 3.5 (–3.5, 10.9) 0.34 6.4 (–2.0, 15.6) 0.14 0.60
Lag 3 –0.9 (–8.7, 7.5) 0.82 –1.9 (–13.8, 11.7) 0.78 0.90
Lag 4 –4.2 (–10.5, 2.7) 0.22 2.1 (–7.9, 13.2) 0.69 0.30
Lag 5 –2.8 (–7.9, 2.6) 0.30 –4.3 (–12.1, 4.2) 0.31 0.76
Models were adjusted for age, BMI, calendar year, pack-years, medication use, season, fasting glucose level, alcohol 
consumption, and apparent temperature.Fang et al.
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markers in the circulatory system beginning 
with early exposure and reaching the great-
est concentration several days later. Although 
we do not know of previous investigations 
between BC and VEGF, previous studies have 
investigated associations between residential 
BC and IL-6 (Delfino et al. 2008, 2009). 
In these small panel studies of elderly Los 
Angeles area residents with CHD followed 
for 12 weeks, increases in IL-6 were observed 
with BC concentrations averaged over 24 hr 
and over 3 days. Further experimental and 
observational studies with extended measure-
ments are needed to investigate the timing 
of responses.
Inflammatory markers were also associ-
ated with BC exposure among individuals with 
diabetes in this study but over a wider range of 
exposure windows. Specifically, IL-1β, IL-6, 
IL-8, and TNF-α were associated with BC. 
Both IL-1β and TNF-α appear to be regula-
tors of PM-induced production and release of 
IL-6 and IL-8 (Herseth et al. 2008; Ishii et al. 
2004; Jiménez et al. 2002), which suggests that 
associations for IL-1β and TNF-α would pre-
cede those. This may help to explain why we 
observed associations between IL-1β and BC 
averages starting on the same day and associa-
tions between BC and IL-8 and IL-6 starting at 
later lags, but this does not explain the appar-
ent lag in the association with TNF-α. With 
the exclusion of those individuals with CHD, 
point estimates for IL-1β and TNF-α were 
similar in the restricted and unrestricted analy-
ses, suggesting that individuals with CHD did 
not account for these associations. Both IL-8 
and TNF-α are elevated in individuals with 
diabetes and may be involved in its risk and 
development (Duncan et al. 2003; Herder et al. 
2005; Plomgaard et al. 2007; Pradhan et al. 
2001; Spranger et al. 2003). IL-1β is produced 
by pancreatic β cells, and it is thought that 
high glucose levels lead to the production of β 
cells, which in turn leads to the production and 
release of IL-1β (Larsen et al. 2007). Thus, for 
those with diabetes, exposure to BC may espe-
cially affect IL-1β, which in turn may play a 
role in the elaboration of additional cytokines. 
We also found inverse associations between 
IL-1β and BC among individuals without dia-
betes, and it is unclear why increasing exposure 
would lead to decreasing IL-1β. Further, we 
also found that the presence of both CHD 
and diabetes conferred the greatest sensitivity 
to BC-associated changes in IL-6 and IL-8. 
Further studies are needed to investigate the 
effects of multiple comorbidities on pollution-
related health effects.
Although studies have noted evidence of 
increased vulnerability of individuals with dia-
betes to various cardiac and systemic effects of 
PM air pollution, few studies have specifically 
reported associations between inflammatory 
markers and BC. In a study of individuals with 
diabetes in the Boston area, BC averaged over 
the previous 24 hr up to 6 days was found to be 
most strongly associated with increased levels of 
adhesion molecules involved in inflammation 
and endothelial function [soluble intercellular 
adhesion molecule-1 (sICAM-1) and soluble 
vascular adhesion molecule-1 (sVCAM-1)] 
(O’Neill et al. 2007), whereas null associations 
were observed with sulfate PM, and weaker 
associations were found with PM2.5. Although 
our study did not investigate adhesion mol-
ecules, our present findings are consistent with 
these previous findings. In another study con-
ducted in the Midwest among non  smoking 
elderly individuals with comorbidities includ-
ing diabetes, IL-6 increased, although not sig-
nificantly, with increasing 5-day average BC 
(Dubowsky et al. 2006), consistent with our 
findings for IL-6. However, contrary to our 
findings, CRP was positively associated with 
5-day average BC in the Dubowsky et al. 
(2006) study. In our study, point estimates 
for CRP were in both directions and widely 
overlapped the null. Differences in the study 
population may explain these different find-
ings because the Dubowsky et al. (2006) study 
population was primarily female, whereas ours 
was entirely male.
There are a number of strengths to this 
study. One is the use of individual-level pre-
dictions of BC concentrations from a vali-
dated spatiotemporal land-use regression 
model, which we considered to be a surrogate 
for primary traffic PM. Specifically, the spatial 
variability of BC on a given day reflected the 
variability of traffic in the region and was the 
basis of the BC model developed and used 
for this study. Although non  residential expo-
sure to BC not captured in the prediction 
model may have introduced some exposure 
Table 5. Percent change in blood marker per IQR (0.36 μg/m3) increase in daily BC by diabetes status.
Marker/single-day  
exposure lag
Without diabetes With diabetes Interaction 
p-value Change [% (95% CI)] p-Value Change [% (95% CI)] p-Value
IL-1β
Lag 0 –4.3 (–10.4, 2.3) 0.20 13.4 (–5.5, 36.0) 0.18 0.08
Lag 1 –5.3 (–11.6, 1.5) 0.12 17.0 (1.0, 35.5) 0.04 0.01
Lag 3 –12.2 (–20.3, –3.3) 0.01 27.4 (0.9, 60.8) 0.04 < 0.01
Lag 4 –7.4 (–13.9, –0.6) 0.03 46.1 (18.8, 79.6) < 0.001 < 0.001
Lag 5 –6.3 (–12.7, 0.6) 0.07 25.1 (6.4, 46.9) 0.01 < 0.001
IL-6
Lag 0 –1.8 (–10.2, 7.4) 0.69 6.9 (–11.9, 29.8) 0.50 0.41
Lag 1 –4.7 (–12.9, 4.1) 0.28 6.5 (–12.8, 30.0) 0.54 0.31
Lag 3 –0.8 (–11.4, 11.0) 0.88 55.1 (16.7, 106.3) < 0.01 < 0.01
Lag 4 –2.6 (–10.1, 5.6) 0.52 37.4 (2.0, 85.0) 0.04 0.02
Lag 5 –1.9 (–9.6, 6.4) 0.64 16.0 (–6.9, 44.5) 0.19 0.15
IL-8
Lag 0 0.8 (–3.5, 5.2) 0.73 2.5 (–9.4, 15.9) 0.70 0.79
Lag 1 –1.4 (–5.1, 2.5) 0.48 2.3 (–10.1, 16.5) 0.73 0.58
Lag 3 –4.7 (–10.1, 1.0) 0.10 13.4 (–4.0, 34.1) 0.14 0.05
Lag 4 –2.7 (–6.9, 1.7) 0.22 19.9 (5.3, 36.4) 0.01 < 0.01
Lag 5 –0.1 (–3.9, 3.8) 0.95 11.4 (–0.3, 24.4) 0.06 0.06
VEGF
Lag 0 5.0 (–1.2, 11.5) 0.12 –6.9 (–18.9, 6.8) 0.30 0.53
Lag 1 1.5 (–4.8, 8.1) 0.65 –10.4 (–24.1, 5.9) 0.20 0.69
Lag 3 –2.1 (–9.0, 5.3) 0.56 15.3 (–6.7, 42.6) 0.19 0.02
Lag 4 –0.6 (–6.1, 5.1) 0.82 12.5 (–7.2, 36.5) 0.23 < 0.001
Lag 5 2.4 (–2.7, 7.7) 0.36 4.1 (–12.2, 23.5) 0.64 0.04
TNF-α
Lag 0 –0.2 (–4.9, 4.7) 0.93 –3.9 (–14.2, 7.6) 0.49 0.10
Lag 1 –1.1 (–6.0, 4.0) 0.66 1.4 (–9.9, 14.1) 0.82 0.16
Lag 3 –3.8 (–10.5, 3.4) 0.30 17.7 (0.3, 38.1) 0.05 0.14
Lag 4 –1.6 (–6.1, 3.1) 0.49 27.8 (10.0, 48.4) < 0.01 0.22
Lag 5 –0.4 (–4.8, 4.2) 0.87 12.4 (0.4, 25.8) 0.04 0.85
sTNF-RII
Lag 0 0.8 (–1.3, 2.9) 0.47 –2.7 (–6.9, 1.8) 0.23 0.15
Lag 1 0.4 (–1.9, 2.8) 0.74 –4.3 (–9.3, 1.0) 0.11 0.10
Lag 3 0.2 (–2.7, 3.2) 0.88 –2.3 (–7.6, 3.3) 0.42 0.42
Lag 4 0.7 (–1.7, 3.2) 0.56 0.7 (–4.0, 5.6) 0.78 0.99
Lag 5 1.1 (–1.1, 3.3) 0.34 –0.3 (–5.3, 5.0) 0.92 0.63
CRP
Lag 0 –1.0 (–6.2, 4.5) 0.72 3.0 (–8.6, 16.2) 0.63 0.55
Lag 1 4.6 (–1.3, 10.8) 0.13 6.2 (–6.0, 20.0) 0.34 0.82
Lag 3 –1.3 (–8.5, 6.5) 0.74 –0.1 (–15.3, 17.8) 0.99 0.90
Lag 4 –1.8 (–7.4, 4.2) 0.55 –9.0 (–21.9, 6.1) 0.23 0.36
Lag 5 –3.4 (–8.0, 1.3.0) 0.16 –0.4 (–14.5, 16.0) 0.96 0.70
Models were adjusted for age, BMI, calendar year, pack-years, medication use, season, fasting glucose level, alcohol 
consumption, and apparent temperature.Residential black carbon and systemic inflammation
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measurement error, we believe that this error 
is small compared with exposure misclassifica-
tion introduced from the use of fixed ambient 
monitoring data, which is the traditional expo-
sure assessment method in large air pollution 
studies. An additional strength of this study 
is the well-characterized study population and 
our ability to adjust for a number of poten-
tially important between- and within-person 
confounders in our statistical models.
As with any epidemiological study, how-
ever, ours is not without limitations. One lim-
itation of concern is the lack of information 
on copollutants. We did not examine other 
pollutants such as total PM2.5 or PM2.5 com-
ponents other than BC in this study. Because 
the BC model is based largely on the daily 
spatial variation exhibited by BC, it is unlikely 
that total PM2.5 or any other copollutant was 
responsible for the effects we observed for BC. 
Other components of PM2.5, such as sulfates 
and organic PM, are more homogeneous over 
the study region. Further, although we can-
not completely rule out confounding by a 
copollutant, the correlations between BC and 
PM2.5, carbon monoxide, and nitrogen diox-
ide, which are related to traffic pollution, have 
been shown to be strong (Delfino et al. 2008; 
Ren et al. 2011), whereas the correlation 
between BC and sulfate, which is associated 
with coal-burning power plants, is weaker 
(Ren et al. 2011). Thus, even though some of 
the observed associations may be confounded 
by correlated exposures, it is likely that the 
potential confounding copollutants are traffic 
related as opposed to non  mobile. Further, we 
acknowledge that although BC was used as a 
surrogate of TRPs, the most toxic component 
of TRPs is still unknown, so BC may not 
fully represent the most toxic aspect of TRP 
exposure. It is also possible that some other 
sources have contributed to BC measurements 
in the area, but we expect this would add only 
a small amount of exposure misclassification. 
Finally, the findings from this study may not 
be generalizable to females, younger individu-
als, and non  white populations if the biological 
responses to BC differ in these populations.
Conclusions
We observed positive associations between 
markers of inflammation and residential BC 
among older men with CHD and diabetes. 
Such associations were not observed when 
observations from the entire cohort were 
included in the model. Whether exposure to 
BC is causally related to the development of 
CHD and diabetes is unclear. However, the 
results of this study support the conclusion 
that systemic inflammatory responses occur 
subsequent to BC exposure among those with 
CHD and diabetes.
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